This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (cancelled)

Claim 12 (new): A method for alleviating retinoid induced skin injury comprising administering an effective amount of an erb inhibitor to a patient in need thereof.

Claim 13 (new): A method according to claim 12 in which said erb inhibitor is a compound represented by the formula



wherein Q is



p is 0 or 1;

X is -D-E-F and Y is $-SR^4$, $-OR^4$, $-NHR^3$, or hydrogen, or X is $-SR^4$, $-OR^4$, $-NHR^3$, or hydrogen, and Y is -D-E-F;

D is 



or absent;

E is  ;

F is  ;

provided that when E is -S- or  , D is not



R^1 is hydrogen, halogen, or C_1-C_6 alkyl;

R^2, R^3, and R^4 are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -$(CH_2)_n$-N-hexahydroazepine or substituted C_1-C_6 alkyl, wherein the

substituents are selected from OH, -NH_2, or -N-B, A and B are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$OH, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-N-pyridyl, -$(CH_2)_n$-imidazoyl, or -$(CH_2)_n$-N-imidazoyl;

E^1, E^2, and E^3 are independently halogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, nitro, C_1-C_6 perfluoroalkyl, hydroxy,

C_1-C_6 acyloxy, -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -NH(C_3-C_8 cycloalkyl), -N(C_3-C_8 cycloalkyl)$_2$, hydroxymethyl, C_1-C_6 acyl, cyano, azido, C_1-C_6 thioalkyl, C_1-C_6 sulfinylalkyl, C_1-C_6 sulfonylalkyl, C_3-C_8 thiocycloalkyl, C_3-C_8 sulfinylcycloalkyl, C_3-C_8 sulfonylcycloalkyl, mercapto, C_1-C_6 alkoxycarbonyl, C_3-C_8 cycloalkoxycarbonyl, C_2-C_4 alkenyl, C_4-C_8 cycloalkenyl, or C_2-C_4 alkynyl;

R^5 is hydrogen, halogen, C_1-C_6-perfluoroalkyl, 1,1-difluoro(C_1-C_6)alkyl, C_1-C6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-piperazinyl, -$(CH_2)_n$-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -C=CH_2, -CH=CH-(C_1-C_6)alkyl,

-$(CH_2)_n$-N-hexahydroazepine, -$(CH_2)_n NH_2$, -$(CH_2)_n$NH(C_1-C_6alkyl), -$(CH_2)_n$N(C_1-C_6 alkyl)$_2$, -1-oxo(C_1-C_6)alkyl, carboxy, (C_1-C_6) alkyloxycarbonyl, N-(C_1-C_6)alkylcarbamoyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z^1, Z^2, Z^3 or a monocyclic heteroaryl group, and each C_1-C_6 alkyl group can be substituted with -OH, -NH_2 or -NAB, where A and B are as defined above, R^6 is hydrogen or C_1-C_6 alkyl; and

n is 1 to 4, p is 0 and 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

Claim 14 (new): A method according to claim 13 wherein the erb inhibitor is 5-(4-methyl-piperazin-1-yl)-pent-2-ynoic acid [4-(3-chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide or N^4-(3-bromo-phenyl)-N^6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine.

Claim 15 (new): A method according to Claim 12 wherein said erb inhibitor is a compound represented by the Formula



wherein X is -D-E-F and Y is -SR^4, halogen, -OR^4, -NHR^3, or hydrogen,
or X is -SR^4, halogen, -OR^4, -NHR^3, or hydrogen, and Y is -D-E-F;

D is 



or absent;

E is 

F is 

provided that when E is  -S- or -S-, D is not



R^1 is hydrogen, halogen, or C_1-C_6 alkyl;

R^2, R^3, and R^4 are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -$(CH_2)_n$-N-hexahydroazepine or substituted C_1-C_6 alkyl, wherein the substituents are selected from -OH, -NH_2, or -N-B, A and B are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$OH, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6-)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-N-pyridyl, -$(CH_2)_n$-imidazoyl, or -$(CH_2)_n$-N-imidazoyl;

Z^1, Z^2, or Z^3 are independently hydrogen, halogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, nitro, C_1-C_6 perfluoroalkyl, hydroxy, C_1-C_6 acyloxy, -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -NH(C_3-C_8 cycloalkyl), -N(C_3-C_8 cycloalkyl)$_2$, hydroxymethyl, C_1-C_6 acyl, cyano, azido, C_1-C_6 thioalkyl, C_1-C_6 sulfinylalkyl, C_1-C_6 sulfonylalkyl, C_3-C_8 thiocycloalkyl, C_3-C_8 sulfinylcycloalkyl, C_3-C_8 sulfonylcycloalkyl, mercapto, C_1-C_6 alkoxycarbonyl, C_3-C_8 cycloalkoxycarbonyl, C_2-C_4 alkenyl, C_4-C_8 cycloalkenyl, or C_2-C_4 alkynyl;

R^5 is hydrogen, halogen, C_1-C_6-perfluoroalkyl, 1,1-difluoro(C_1-C_6)alkyl, C_1-C_6alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-piperazinyl, -$(CH_2)_n$-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino,G=CH_2, -CH=CH-(C_1-C_6)alkyl,

-$(CH_2)_n$-N-hexahydroazepine, -$(CH_2)_n$$NH_2$, -$(CH_2)_n$NH($C_1$-$C_6$alkyl), -$(CH_2)_n$N($C_1$-$C_6$alkyl)$_2$, -1-oxo($C_1$-$C_6$)alkyl, carboxy, ($C_1$-$C_6$)alkyloxycarbonyl,

N-(C_1-C_6)alkylcarbamoyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z^1, Z^2, Z^3 or a monocyclic heteroaryl group, and each C_1-C_6 alkyl group above in R^5 can be substituted with -OH, -NH_2 or -NAB, where A and B are as defined above, R^6 is hydrogen or C_1-C_6 alkyl; R^{13} is hydrogen or halogen; and n is 1 to 4, p is 0 or 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

Claim 16 (new): A method according to claim 15 wherein said compound is N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide or N-[4-(3-bromo-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.

Claim 17 (new): A method for alleviating the dermal side effects associated with the topical administration of retinoids comprising the administration of an effective amount of an erb inhibitor to a patient in need thereof.

Claim 18 (new): A method according to claim 17 in which said erb inhibitor is a compound represented by the formula



wherein Q is



p is 0 or 1;

X is -D-E-F and Y is $-SR^4$, $-OR^4$, $-NHR^3$, or hydrogen, or X is $-SR^4$, $-OR^4$, $-NHR^3$, or hydrogen, and Y is -D-E-F;

D is 



or absent;

E is 

F is 

provided that when E is -S- or  -S-, D is not



R^1 is hydrogen, halogen, or C_1-C_6 alkyl;

R^2, R^3, and R^4 are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -$(CH_2)_n$-N-hexahydroazepine or substituted C_1-C_6 alkyl, wherein the

substituents are selected from OH, -NH_2, or -N-B, A and B are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$OH, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-N-pyridyl, -$(CH_2)_n$-imidazoyl, or -$(CH_2)_n$-N-imidazoyl;

E^1, E^2, and E^3 are independently halogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, nitro, C_1-C_6 perfluoroalkyl, hydroxy, C_1-C_6 acyloxy, -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -NH(C_3-C_8 cycloalkyl), -N(C_3-C_8 cycloalkyl)$_2$, hydroxymethyl, C_1-C_6 acyl, cyano, azido, C_1-C_6 thioalkyl, C_1-C_6 sulfinylalkyl, C_1-C_6 sulfonylalkyl, C_3-C_8 thiocycloalkyl, C_3-C_8 sulfinylcycloalkyl, C_3-C_8 sulfonylcycloalkyl, mercapto, C_1-C_6 alkoxycarbonyl, C_3-C_8 cycloalkoxycarbonyl, C_2-C_4 alkenyl, C_4-C_8 cycloalkenyl, or C_2-C_4 alkynyl;

R^5 is hydrogen, halogen, C_1-C_6-perfluoroalkyl, 1,1-difluoro(C_1-C_6)alkyl, C_1-C6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-piperazinyl, -$(CH_2)_n$-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -C=CH_2, -CH=CH-(C_1-C_6)alkyl,

-$(CH_2)_n$-N-hexahydroazepine, -$(CH_2)_n$$NH_2$, -$(CH_2)_n$NH($C_1$-$C_6$alkyl), -$(CH_2)_n$N($C_1$-$C_6$ alkyl)$_2$, -1-oxo(C_1-C_6)alkyl, carboxy, (C_1-C_6) alkyloxycarbonyl, N-(C_1-C_6)alkylcarbamoyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z^1, Z^2, Z^3 or a monocyclic heteroaryl group,

and each C_1-C_6 alkyl group can be substituted with -OH, -NH_2 or -NAB, where A and B are as defined above, R^6 is hydrogen or C_1-C_6 alkyl; and n is 1 to 4, p is 0 and 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

Claim 19 (new): A method according to claim 17 wherein the erb inhibitor is 5-(4-methyl-piperazin-1-yl)-pent-2-ynoic acid [4-(3-chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide or N^4-(3-bromo-phenyl)-N^6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine.

Claim 20 (new): A method according to Claim 17 wherein said erb inhibitor is a compound represented by the Formula



I

wherein X is -D-E-F and Y is -SR^4, halogen, -OR^4, -NHR^3, or hydrogen, or X is -SR^4, halogen, -OR^4, -NHR^3, or hydrogen, and Y is -D-E-F;

D is 

or absent;

E is  ;

F is  ;

provided that when E is  or  , D is not



R^1 is hydrogen, halogen, or C_1-C_6 alkyl;

R^2, R^3, and R^4 are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -$(CH_2)_n$-N-hexahydroazepine or substituted C_1-C_6 alkyl, wherein the substituents are selected from -OH, -NH_2, or  , A and B are independently hydrogen, C_1-C_6 alkyl, -$(CH_2)_n$OH, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-N-piperazinyl, -$(CH_2)_n$-N_1-piperazinyl[N_4-(C_1-C_6-)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-N-pyridyl, -$(CH_2)_n$-imidazoyl, or -$(CH_2)_n$-N-imidazoyl;

Z^1, Z^2, or Z^3 are independently hydrogen, halogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkoxy, nitro, C_1-C_6 perfluoroalkyl, hydroxy, C_1-C_6 acyloxy, -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, -NH(C_3-C_8 cycloalkyl), -N(C_3-C_8 cycloalkyl)$_2$, hydroxymethyl, C_1-C_6 acyl, cyano, azido, C_1-C_6 thioalkyl, C_1-C_6 sulfinylalkyl, C_1-C_6 sulfonylalkyl, C_3-C_8 thiocycloalkyl,

C_3-C_8 sulfinylcycloalkyl, C_3-C_8 sulfonylcycloalkyl, mercapto, C_1-C_6 alkoxycarbonyl, C_3-C_8 cycloalkoxycarbonyl, C_2-C_4 alkenyl, C_4-C_8 cycloalkenyl, or C_2-C_4 alkynyl;

R^5 is hydrogen, halogen, C_1-C_6-perfluoroalkyl, 1,1-difluoro(C_1-C_6)alkyl, C_1-C_6alkyl, -$(CH_2)_n$-N-piperidinyl, -$(CH_2)_n$-piperazinyl, -$(CH_2)_n$-piperazinyl[N_4-(C_1-C_6)alkyl], -$(CH_2)_n$-N-pyrrolidyl, -$(CH_2)_n$-pyridinyl, -$(CH_2)_n$-N-imidazoyl, -$(CH_2)_n$-N-morpholino, -$(CH_2)_n$-N-thiomorpholino, -$C(=CH_2)H$, -CH=CH-(C_1-C_6)alkyl, -$(CH_2)_n$-N-hexahydroazepine, -$(CH_2)_nNH_2$, -$(CH_2)_nNH(C_1$-C_6alkyl), -$(CH_2)_nN(C_1$-C_6alkyl)$_2$, -1-oxo(C_1-C_6)alkyl, carboxy, (C_1-C_6)alkyloxycarbonyl, N-(C_1-C_6)alkylcarbamoyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z^1, Z^2, Z^3 or a monocyclic heteroaryl group, and each C_1-C_6 alkyl group above in R^5 can be substituted with -OH, -NH_2 or -NAB, where A and B are as defined above, R^6 is hydrogen or C_1-C_6 alkyl; R^{13} is hydrogen or halogen; and n is 1 to 4, p is 0 or 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

Claim 21 (new): A method according to claim 17 wherein said compound is N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide or N-[4-(3-bromo-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.